EGFR and cancer: Erlotinib (Figure 1A), is an EGFR tyrosine kinase inhibitor that prevents intracellular phosphorylation of EGFR in cancer cells, preventing downstream signaling and causing cancer cell death (Haas-Kogan et al., 2005).